Prospects for controlling future pandemics of influenza

被引:16
作者
Robertson, James S. [1 ]
Inglis, Stephen C. [1 ]
机构
[1] Natl Inst Biol Stand & Controls, Potters Bar EN6 3QG, Herts, England
关键词
Influenza; Vaccine; Anti-virals; Pandemics; Surveillance; Pandemic preparedness; CANDIDATE VACCINE VIRUSES; REVERSE GENETICS; A VIRUS; HEMAGGLUTININ; CELLS; IMMUNOGENICITY; EVENT;
D O I
10.1016/j.virusres.2011.09.024
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Pandemic influenza remains one of the most serious threats to global public health and continued global vigilance to monitor emerging threats is crucial. Of the weapons available to control a pandemic, vaccination is potentially the most powerful, but there are currently serious limitations to timely availability of vaccine supply in an emergency. Many novel influenza vaccines are in development, some of which have the potential to deliver the massive quantities of vaccine that would be required in a pandemic in a short period of time. However, for the foreseeable future, it is likely that the principal vaccine that will be deployed in a pandemic will be an inactivated egg-derived vaccine of the kind that has been available for several decades. This review will focus on the practical hurdles that need to be surmounted to deliver large amounts of safe and effective pandemic vaccine to the general public. There needs to be a continued focus on improvement to the vaccine response system that will require close collaboration between influenza and vaccine experts, manufacturers, regulators and public health authorities around the world. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:39 / 46
页数:8
相关论文
共 95 条
[1]  
[Anonymous], 2009, Wkly Epidemiol Rec, V84, P505
[2]  
[Anonymous], 2011, Wkly Epidemiol Rec, V86, P93
[3]  
[Anonymous], 2011, PANFL PAND INFL VACC
[4]  
Aoki FY., 1998, Textbook of Influenza, P457
[5]   MF59®-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis [J].
Banzhoff, Angelika ;
Pellegrini, Michele ;
Del Giudice, Giuseppe ;
Fragapane, Elena ;
Groth, Nicola ;
Podda, Audino .
INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2008, 2 (06) :243-249
[6]   Potent CD8+ T-Cell Immunogenicity in Humans of a Novel Heterosubtypic Influenza A Vaccine, MVA-NP+M1 [J].
Berthoud, Tamara K. ;
Hamill, Matthew ;
Lillie, Patrick J. ;
Hwenda, Lenias ;
Collins, Katharine A. ;
Ewer, Katie J. ;
Milicic, Anita ;
Poyntz, Hazel C. ;
Lambe, Teresa ;
Fletcher, Helen A. ;
Hill, Adrian V. S. ;
Gilbert, Sarah C. .
CLINICAL INFECTIOUS DISEASES, 2011, 52 (01) :1-7
[7]  
Bucher D, 2011, HIGH YIELD REASSORTA
[8]  
Cabinet Office, 2010, NAT RISK REG CIV EM, V2010, P7
[9]   Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix™] -: A review of its use as an active immunization against influenza A subtype H5N1 virus [J].
Carter, Natalie J. ;
Plosker, Greg L. .
BIODRUGS, 2008, 22 (05) :279-292
[10]  
Chan M., 2009, World now at the start of 2009 influenza pandemic